Background
Methods
Patients
Next-generation sequencing
Statistical and outcome analysis
Results
Patient demographic characteristics
Characteristics | Total patients, N = 438 (100%) | MET wild type, N = 407 (92.9%) | MET alteration(s), N = 31 (7.1%) | P values* |
---|---|---|---|---|
Age at diagnosis (years) (median, CI 95%) | 57.5 (54.5–59.1) | 57.7 (55.3–59.2) | 53.8 (49.0–62.2) | 0.791 |
Gender | 0.288 | |||
Women | 228 (52.1%) | 209 (91.7%) | 19 (8.3%) | |
Men | 210 (47.9%) | 198 (94.3%) | 12 (5.7%) | |
Ethnicity | ||||
Caucasian | 303 (69.2%) | 284 (93.7%) | 19 (6.3%) | 0.326 |
Asian | 52 (11.9%) | 46 (88.5%) | 6 (11.5%) | 0.188 |
Hispanic | 30 (6.8%) | 28 (93.3%) | 2 (6.7%) | 0.928 |
African American | 9 (2.1%) | 8 (88.9%) | 1 (11.1%) | 0.637 |
Middle Eastern | 5 (1.1%) | 5 (100%) | 0 (0%) | 0.998 |
Unknown | 39 (8.9%) | 36 (92.3%) | 3 (7.7%) | 0.875 |
Type of cancer | ||||
Gastrointestinal | 123 (28.1%) | 118 (95.9%) | 5 (4.1%) | 0.132 |
Brain | 109 (24.9%) | 107 (98.2%) | 2 (1.8%) | 0.026** |
Lung | 102 (23.2%) | 90 (88.2%) | 12 (11.8%) | 0.039** |
Breast | 51 (11.6%) | 45 (88.2%) | 6 (11.8%) | 0.172 |
Genitourinary | 18 (4.1%) | 15 (83.3%) | 3 (16.7%) | 0.120 |
Head and neck | 10 (2.3%) | 9 (90.0%) | 1 (10.0%) | 0.717 |
Gynecologic | 7 (1.6%) | 6 (85.7%) | 1 (14.3%) | 0.465 |
Melanoma | 5 (1.1%) | 4 (80.0%) | 1 (20.0%) | 0.285 |
Hematologic | 3 (0.7%) | 3 (100%) | 0 (0%) | 0.998 |
Othera | 10 (2.3%) | 10 (100%) | 0 (0%) | 0.998 |
Presence of metastasis or recurrence at the time of blood draw | ||||
Yes | 312 (71.2%) | 284 (91.0%) | 28 (9.0%) | 0.024** |
No | 126 (28.8%) | 123 (97.6%) | 3 (2.4%) |
MET alterations and associations with patient characteristics
Univariate analyses
Multivariate analyses
MET wild type, N = 407 | MET altered, N = 31 | Univariable | Multivariable | |||||
---|---|---|---|---|---|---|---|---|
Characteristics | Wald | Odds ratio (CI 95%) | P value | Wald | Odds ratio (CI 95%) | P value | ||
Type of cancer | ||||||||
Brain (n = 109)** | 107 (26.3%) | 2 (6.5%) | 4.94 | 0.19 (0.05–0.83) | 0.026** | – | – | – |
Lung (n = 102) | 90 (22.1%) | 12 (38.7%) | 4.26 | 2.22 (1.04–4.76) | 0.039 | – | – | – |
Presence of metastasis or recurrence at the time of blood draw (n = 312) | 284 (69.8%) | 28 (90.3%) | 5.13 | 4.0 (1.2–14.3) | 0.024 | – | – | – |
Genetic alteration type | ||||||||
TP53 (n = 149) | 129 (31.7%) | 20 (64.5%) | 12.2 | 3.85 (1.82–8.33) | < 0.001 | 10.9 | 3.7 (1.7–8.3) |
0.001
|
EGFR (n = 53) | 43 (10.6%) | 10 (32.4%) | 11.2 | 4.0 (1.79–9.1) | 0.001 | – | – | – |
PIK3CA (n = 42) | 35 (8.6%) | 7 (22.6%) | 5.93 | 3.1 (1.25–7.7) | 0.015 | – | – | – |
BRAF (n = 27) | 22 (5.4%) | 5 (16.1%) | 5.14 | 3.3 (1.2–10.0) | 0.023 | – | – | – |
ARID1A (n = 19) | 15 (3.7%) | 4 (12.9%) | 5.14 | 3.85 (1.2–12.5) | 0.023 | – | – | – |
ALK (n = 14) | 11 (2.7%) | 3 (9.7%) | 3.94 | 3.85 (1.02–14.3) | 0.047 | – | – | – |
PTEN (n = 9) | 6 (1.5%) | 3 (9.7%) | 7.72 | 7.1 (1.7–33.3) | 0.007 | 9.12 | 11.1 (2.3–50.0) |
0.003
|
Metastatic sites | ||||||||
Lymph node (n = 139) | 123 (30.2%) | 16 (51.6%) | 5.77 | 2.4 (1.2–5.3) | 0.016 | – | – | – |
Bone (n = 102) | 88 (21.6%) | 14 (45.2%) | 8.26 | 2.9 (1.4–6.3) | 0.004 | 7.34 | 2.9 (1.35–6.25) |
0.007
|
No metastases (n = 147)** | 145 (35.6%) | 2 (6.5%) | 7.96 | 0.13 (0.03–0.5) | 0.005** | – | – | – |
Variables | Median N of alterations (95% CI) (range) | P value (univariable) | t statistic (multivariable) | P value (multivariable) |
---|---|---|---|---|
Overall | 1 (1–1) (0–26) | |||
Tumor type | ||||
Gastrointestinal | 2 (1–2) (0–26) | 0.031 | – | – |
Brain | 0 (0–0) (0–5) | < 0.001 | – | – |
Lung | 2 (2–3) (0–21) | < 0.001 | – | – |
Genomic alterations | ||||
MET | 4 (3–6) (1–21) | < 0.001 | 3.35 |
0.001
|
TP53 | 3 (3–3) (1–21) | < 0.001 | 6.86 |
< 0.001
|
EGFR | 3 (3–4) (1–26) | < 0.001 | – | – |
PIK3CA | 5 (4–6) (1–26) | < 0.001 | 7.31 |
< 0.001
|
BRAF | 5 (4–6) (1–26) | < 0.001 | 6.54 |
< 0.001
|
KRAS | 4 (3–4) (1–26) | < 0.001 | 6.01 |
< 0.001
|
MYC | 5 (3–6) (2–7) | < 0.001 | 2.70 |
0.007
|
Metastatic/recurrence at the time of blood draw | 2 (1–2) (0–26) | < 0.001 | – | – |
Metastatic sites | ||||
Lymph node | 2 (2–3) (0–21) | < 0.001 | 2.05 |
0.041
|
Bone | 2 (2–3) (0–26) | < 0.001 | – | – |
Liver | 2 (2–3) (0–26) | < 0.001 | – | – |
Lung | 2 (1–3) (0–19) | 0.010 | – | – |
Brain | 2 (1–3) (0–21) | < 0.001 | – | – |
Adrenal | 2 (2–4) (0–20) | < 0.001 | 2.06 |
0.040
|
MET alterations and survival outcomes
Overall survival
Univariable | Multivariable | ||||
---|---|---|---|---|---|
Characteristics | Median time (months) (std. error) | P value | Wald | Hazard ratio (CI 95%) | P value |
Type of cancer | |||||
Gastrointestinal (n = 123) vs not | 36.3 (4.5) vs 71.6 (6.5) | 0.002 | – | – | – |
Brain (n = 109) vs not** | 95.0 (50.1) vs 51.5 (5.9) | 0.003 | – | – | – |
Lung (n = 102) vs not | 31.8 (6.0) vs 61.0 (7.4) | 0.002 | 9.59 | 1.7 (1.21–4.04) |
0.002
|
Breast (n = 51) vs not | 104.8 (20.3) vs 50.0 (5.6) | 0.027 | |||
Genetic alteration type | |||||
MET (n = 31) vs not | 30.6 (6.2) vs 58.4 (6.3) | 0.013 | – | – | – |
TP53 (n = 149) vs not | 42.1 (6.1) vs 66.5 (10.3) | 0.003 | – | – | – |
PIK3CA (n = 42) vs not | 43.2 (10.6) vs (58.4 (6.3) | 0.013 | – | – | – |
ARID1A (n = 19) vs not | 24.8 (6.2) vs 58.4 (6.8) | 0.002 | 7.98 | 2.7 (1.25–4.0) |
0.005
|
KRAS (n = 50) vs not | 18.3 (7.3) vs 59.7 (6.5) | < 0.001 | 15.68 | 2.1 (1.5–3.12) |
< 0.001
|
ALK (n = 14) vs not | 31.3 (9.0) vs 58.3 (6.7) | 0.015 | 5.76 | 2.04 (1.14–3.7) |
0.016
|
SMAD4 (n = 12) vs not | 21.7 (8.2) vs 58.3 (6.2) | 0.007 | – | – | – |
MYC (n = 20) vs not | 22.2 (3.9) vs 59.1 (6.5) | < 0.001 | 7.59 | 2.17 (1.24–3.77) |
0.006
|
Metastatic/recurrence at the time of blood draw vs not | 53.6 (4.9) vs NR | 0.011 | – | – | – |
Metastatic sites | |||||
Liver (n = 111) vs not | 49.3 (8.2) vs 59.1 (7.9) | 0.023 | 4.85 | 1.4 (1.03–1.89) |
0.028
|
Lymph node (n = 139) vs not | 39.9 (7.4) vs 74.1 (11.1) | < 0.001 | – | – | – |
Time to metastasis/recurrence
Univariable | Multivariable | ||||
---|---|---|---|---|---|
Characteristics | Median time (months) (95% CI) | P value | Wald | Hazard ratio (CI 95%) | P value |
Type of cancer | |||||
Gastrointestinal (n = 123) vs not | 0.67 (0–1.9) vs 14.1 (8.3–19.8) | < 0.001 | – | – | – |
Brain (n = 109) vs not | 42.8 (19.0–66.7) vs 2.5 (0.49–4.4) | < 0.001 |
–
|
–
|
–
|
Lung (n = 102) vs not | 0.6 (0–1.3) vs 14.0 (9.5–18.6) | < 0.001 | – | – | – |
Breast (n = 51) vs not | 30.4 (14.3–46.4) vs 7.0 (3.8–10.2) | 0.001 | 40.03 | 0.33 (0.23–0.47) |
< 0.001
|
Genitourinary (n = 18) vs not | 0 (−) vs 10.1 (6.8–13.4) | 0.020 | – | – | – |
Head and neck (n = 10) vs not | 0 (−) vs 9.8 (6.2–13.4) | 0.015 | – | – | – |
Genetic alteration type | |||||
MET (n = 31) vs not | 1.0 (−) vs 10.4 (6.9–14.0) | 0.003 | 4.05 | 1.47 (1.01–2.13) |
0.044
|
TP53 (n = 149) vs not | 4.1 (0.5–7.7) vs 12.7 (6.1–19.3) | 0.001 | – | – | – |
EGFR (n = 53) vs not | 3.6 (0–8.2) vs 11.4 (7.9–14.8) | 0.003 | – | – | – |
ARID1A (n = 19) vs not | 3.6 (0–10.1) vs 10.0 (6.3–13.7) | 0.013 | – | – | – |
KRAS (n = 50) vs not | 0 (−) vs 11.4 (8.3–13.7) | < 0.001 | – | – | – |
SMAD4 (n = 12) vs not | 0 (−) vs 10.1 (6.7–13.4) | 0.040 | – | – | – |
MYC (n = 20) vs not | 0.2 (0–0.75) vs 10.4 (7.0–13.9) | < 0.001 | – | – | – |
Metastatic sites | |||||
Adrenal (n = 29) vs not | 0 (−--) vs 11.3 (8.0–14.6) | 0.002 | – | – | – |
Bone (n = 102) vs not | 1.5 (0–6.7) vs 11.4 (8.2–14.5) | 0.049 | – | – | – |
Liver (n = 111) vs not | 0.9 (0–2.6) vs 132.3 (9.7–16.9) | < 0.001 | 10.04 | 1.49 (1.16–1.92) |
0.022
|
Lymph node (n = 139) vs not | 0.3 (−) vs 20.1 (14.3–25.9) | < 0.001 | 13.41 | 1.54 (1.22–1.92) |
< 0.001
|
Peritoneal (n = 49) vs not | 0 (−) vs 11.3 (8.1–14.5) | < 0.001 | – | – | – |
Brain (n = 63) vs not | 3.6 (0–7.8) vs 10.4 (7.0–13.9) | 0.045 | – | – | – |
Lung (n = 90) vs not | 1.2 (0–8.0) vs 11.3 (7.7–15.0) | 0.003 | – | – | – |